Yael Weiss, MD, PhD

Yael Weiss received an MD at the Hebrew University in Jerusalem and her PhD in molecular genetics at the Weizmann Institute of Science (Rehovot, Israel). She has more than 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck, and Ultragenyx. In 2020, Yael founded Mahzi Therapeutics to bring therapies to patients with underserved rare genetic neurodevelopmental disorders. Mahzi – which means together in Greek – works closely with patient/family led Foundations to support their drug development efforts and brings therapeutic programs into Mahzi once pre-clinical proof of concept has been established.

Yael is a member of the NIH-driven Bespoke Gene Therapy (BCTG) consortium, the American Society of Gene and Cell Therapy Translational Committee, the N=1 Collaborative, and a 2022 Termeer Fellow. She is a board member/advisor to the ADNP and FOXG1 Foundations.

Eric Marsh, MD, PhD

Eric Marsh is an Attending Physician, Professor of Neurology and Clinical Director of the Neurogenetics Program at the Children’s Hospital of Philadelphia. He is also an Associate Professor of Neurology and Pediatrics at the Perelman School of Medicine, University of Pennsylvania, and the Clinical Director of the Orphan Disease Center at UPenn.

Dr. Marsh’s research program focuses on identifying the genetic, cellular, and network mechanisms of seizures, autism, and cognitive dysfunction in children. His team combines molecular and neurophysiological tools in mouse models to ask questions about the interaction of normal development with single gene mutations to determine how the brain responds to perturbations in development.

His group also takes a translational approach to determine the network and electrophysiological alterations in the brains of children with intractable, early-onset epilepsies. intracranial and scalp EEG from children with intractable focal epilepsies. They extract specific features from the EEG, primarily interictal spikes and sharps, to determine whether they inform about network dynamics or can act as a biomarker for seizure onset or post-surgery prognosis.

Marsh received a BS in biology from Haverford College, an MS and PhD in physiology and neuroscience from New York University, and an MD from the New York School of Medicine.

Wendy Chung, MD, PhD

Wendy Chung is the Chair of Pediatrics at Boston Children’s Hospital/Harvard Medical School. She is a clinical geneticist specializing in neurodevelopmental disorders. Her research extends to the genetic basis of seizures, intellectual disabilities, autism, inherited metabolic conditions, rare disorders and several other diseases including obesity, diabetes, cardiomyopathies, and congenital heart disease. She is the lead PI of large programs in autism genetic research including Simons VIP and SPARK.

Dr Chung, a member of the National Academy of Medicine, was the recipient of the American Academy of Pediatrics Young Investigator Award, the Medical Achievement Award from Bonei Olam, and the New York Academy Medal for Distinguished Contributions in Biomedical Science. Dr. Chung is renowned for her teaching and mentoring. She is a member of the Glenda Garvey Teaching Academy and has won many awards for teaching including the Charles W. Bohmfalk Award for Distinguished Contributions to Teaching, American Medical Women’s Association Mentor Award, and Columbia University Presidential Award for Outstanding Teaching.

Dr Chung received her B.A. in biochemistry and economics from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. from The Rockefeller University in genetics.